Arcadia Biosciences, Inc.

Arcadia Biosciences, Inc. announced the closing of a private placement of securities, raising approximately $4 million before expenses. The offering included pre-funded warrants and Series A-1 and Series A-2 preferred investment options to purchase common stock. The company intends to use the net proceeds for working capital and general corporate purposes. H.C. Wainwright & Co. served as the exclusive placement agent for the transaction.

Arcadia Biosciences, Inc. announced the closing of its previously announced private placement, generating approximately $4 million in gross proceeds. The offering included the sale of 3,883,496 shares of common stock (or pre-funded warrants) and associated Series A-1 and Series A-2 preferred investment options at a purchase price of $1.03 per share. The net proceeds from this financing will be allocated towards working capital and general corporate purposes.

Arcadia Biosciences, Inc. announced it has entered into securities purchase agreements for a private placement expected to generate approximately $4 million in gross proceeds. The offering includes 3,883,496 shares of its common stock (or pre-funded warrants) and associated Series A-1 and Series A-2 preferred investment options, priced at $1.03 per share. The net proceeds from this offering will be utilized for working capital and general corporate purposes.

Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decline from a net income of $2.6 million in the prior year's quarter, with product revenues decreasing to $1.1 million. The company's financial statements indicate substantial doubt about its ability to continue as a going concern due to insufficient cash and ongoing operating losses. During the quarter, Arcadia completed a January 2026 Inducement Offer, generating $2.1 million in proceeds but incurring a $2.9 million loss related to the offer.

Arcadia Biosciences reported a net loss of $4.4 million for the first quarter of 2026, a significant decrease from a net income of $2.6 million in Q1 2025. Total revenues declined 8% to $1.1 million, primarily due to a revenue reserve release in the prior year, despite an 18% increase in Zola coconut water volumes. The company achieved its lowest SG&A expenses in its history, generated $2.1 million from preferred investment option exercises, and plans a new product launch this fall.

Arcadia Biosciences, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the year ended December 31, 2025, to include previously omitted Part III information. This amendment provides details on directors, executive officers, corporate governance, and executive compensation. Key compensation figures for 2025 were disclosed, including Thomas J. Schaefer's total compensation of $300,001 and former CFO Mark Kawakami's $218,425, with no executive bonuses paid for 2025 due to a terminated business combination. The filing also outlined non-employee director compensation and noted the elimination of director meeting attendance fees starting in 2026.

Arcadia Biosciences dismissed Deloitte & Touche as its independent registered public accounting firm on March 30, 2026. The decision was made by the audit committee of the board of directors. While Deloitte's audit reports did not contain adverse opinions, the company had previously identified material weaknesses in its internal control over financial reporting.